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Abstract. The aim of the present study was to investigate the 
efficacy of colorectal cancer (CRC) screening with a three‑tier 
fecal occult blood test (FOBT) in the Chinese population. The 
study was performed between 1987 and 2008 at the Beijing 
Military General Hospital, in a cohort of army service males 
and females aged >50 years. Between 1987 and 2005, a three‑tier 
screening program, comprising guaiac‑based FOBTs (gFOBTs), 
followed by immunochemical FOBTs for positive guaiac test 
samples and then colonoscopy for positive immunochemical 
test subjects, was performed annually. The cohort was followed 
up until 2008. The cohort included 5,104 subjects, of which, 
3,863 subjects participated in screening (screening group) and 
1,241 did not (non‑screening group). The two groups did not 
differ in age, gender or other major risk factors for colon cancer. 
Overall, 36 CRCs occurred in the screening group and 21 in 
the non‑screening group. Compared with the non‑screening 
group, the relative risk for the incidence and mortality of CRC 
was 0.51 [95% confidence interval (CI), 0.30‑0.87] and 0.36 
(95% CI, 0.18‑0.71), respectively, in the screening group. The 
general sensitivity of this three‑tier FOBT was 80.6% (95% CI, 
65.3‑91.1). Thus, annual screening using the three‑tier FOBT 
program may reduce the CRC incidence and mortality rate.
Introduction
Colorectal cancer (CRC) is the second most common type 
of cancer and the second leading cause of cancer‑related 
mortality in developed countries (1). In recent years, the inci-
dence of CRC has markedly increased in China, particularly in 
urban populations. This is likely to be due to the rapid changes 
in social economic factors, such as lifestyle, diet and environ-
ment. As an example, in Beijing, the annual incidence of CRC 
has increased from 16 per 100,000 to 24 per 100,000 in the 
past decade (2).
Screening provides the ability to detect precancerous lesions 
and early‑stage CRC, thus saving lives, and there are numerous 
different screening options presently available (3). Among 
these, the fecal occult blood test (FOBT) is the most common 
test in use for CRC screening. Several large cohort studies have 
demonstrated the effectiveness of FOBT‑based screening in 
Western countries (4‑6); however, no such studies have been 
performed in developing countries thus far. Furthermore, the 
majority of the large‑scale cohort studies have utilized the 
conventional chemical guaiac‑based FOBT (gFOBT) method. 
The gFOBT has a high false‑positive rate (range, 2‑13%) (7,8) 
and other limitations, such as the requirement of diet restric-
tion. The latter is particularly troublesome for people in Asian 
countries. The antibody‑based immunochemical method, the 
fecal immunochemical test (FIT), has been demonstrated to 
have test performance characteristics with improved sensitivity 
and specificity compared with those of gFOBT, and it does 
not require any restrictions on diet (7). However, the higher 
costs associated with FIT compared with gFOBT limit its use 
for screening in countries such as China, where healthcare 
resources are limited. The present study evaluates a three‑tier 
FOBT‑based program, and presents the results of a prospective 
longitudinal trial for CRC screening with this program.
Materials and methods
Subjects. The eligible subjects in the present study were 
army officers (retired or non‑retired) aged >50 years, who 
were receiving healthcare from the Beijing Military General 
Hospital (Beijing, China) and lived in the Beijing area. Subjects 
with known CRC, colorectal adenomas, inflammatory bowel 
disease or various types of malignant tumors were excluded 
from the cohort. The study was approved by the Beijing 
Military General Hospital Ethics Committee, and informed 
consent was obtained from each subject.
The present study was a dynamic cohort study, where 
subjects who met the eligibility criteria were recruited on an 
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annual basis. Upon entry into the cohort study, each subject 
received a complete health status check‑up, which included 
a physical examination, chest X‑ray, ECG, abdominal 
ultrasound, mammogram (for females) and serological exami-
nation, including an analysis of glucose and lipid levels. The 
health check‑up data, along with the data from a baseline 
questionnaire (for date of birth, gender, education, family 
history of malignant tumors, lifestyle, medication use, body 
height/weight and previous general health status), were entered 
into a database. The database was updated yearly, based on the 
findings from the annual follow‑up examinations.
At the end of the initial check‑up, each eligible subject 
was asked by physicians for their consent to undergo CRC 
screening. Those who agreed to be screened were included 
in the screening group, and those who refused to be screened 
were included in a non‑screening group. Other than the FOBT 
that was performed in the screening group on an annual basis, 
the subjects in the screening and non‑screening groups were 
investigated in the same manner, with an annual examination 
for other chronic conditions, as detailed above.
The annual FOBT‑based CRC screening began in 
May 1987 and ended in December 2005. Following this, the 
two groups were followed up until December 2008. In 1987, 
there were 3,002 eligible subjects, including 2,260 males and 
742 females, with a mean age of 61.8 years (2,809 subjects were 
aged ≤74 years). The number of subjects in the screening group 
was 2,246, and the number of subjects in the non‑screening 
group was 756. For the subsequent years (1988‑2005), an 
additional 2,102 eligible subjects were entered into the cohort. 
In total, there were 3,863 subjects in the screening group and 
1,241 in the non‑screening group (Fig. 1).
Screening methods. For the screening, each subject provided 
one fecal sample every year for the FOBT, which was 
performed in the Clinical Laboratory of Beijing Military 
General Hospital. No restrictions, with regard to diet, drugs or 
other food items, were imposed on the subjects prior to stool 
collection. Between 1987 and 2005, a three‑tier screening 
program was implemented: gFOBT (rehydrated; produced 
by Baso Diagnostics Inc., Zhuhai, China) was performed, 
followed by FIT (gold gel stripe; provided by WanhuaPuman 
Biological Engineering Co., Ltd., Tech Lt. Comp., Beijing, 
China) for gFOBT‑positive fecal samples, and then colonos-
copy for those who had positive FIT results. According to 
the manufacturer, the positive threshold of FIT was 0.2 µg/
ml. For patients who refused colonoscopy, a double‑contrast 
barium enema (DCBE) was performed. For patients with 
negative (no cancer detected) colonoscopy or DCBE results, 
the aforementioned screening steps were repeated in the 
following year.
On identification of a lesion (polyp, tumor or otherwise) 
during colonoscopy or DCBE, a biopsy (or resection for a 
polyp or tumor) was performed. If a malignant tumor was 
identified, appropriate management was provided according 
to the final pathology, and the subject was regarded as an 
incidence case (the secondary endpoint) and continued to be 
followed up until they succumbed to the disease (the primary 
endpoint). Patients with adenoma were to be followed 
annually, as were the other non‑cancer subjects, following 
complete resection.
Data and statistical analyses. The primary endpoint of the 
follow up was CRC‑related mortality, and the secondary 
endpoint was the incidence of CRC. Overall, 82% of the 
mortalities occurred in the Beijing Military General Hospital, 
and the cause was determined based on a review of the 
medical records (International Classification of Diseases, 
ICD‑9 or ‑10). For the subjects who succumbed elsewhere, a 
telephone interview with the next of kin was performed and 
the cause of death was determined from the death certificate.
A positive predictive value (PPV) was estimated for each 
screening round, while only positive tests followed by colo-
noscopy or DCBE were used in the computation. The general 
sensitivity was evaluated by the number of true positives 
relative to the number of individuals with carcinomas, while 
a positive test result was considered to be a true positive if 
a carcinoma was detected during the entire follow‑up period.
To evaluate potential selection bias, the χ2 test or the 
independent samples t‑test for the baseline characteristics 
[age at baseline, gender, education, family history of malig-
nant tumors, body mass index (BMI), smoking status (never, 
former or current), alcohol intake (none, occasional or regular), 
physical exercise (at least once per week or less), meat intake (at 
least three times per week or less) and aspirin use (regular or 
never)] and status at time of mortality from all of these causes 
were utilized. A χ2 test was used to examine the CRC incidence 
and mortality in the screening and non‑screening groups, and 
the relative risk (RR) and 95% confidence intervals (CIs) were 
Figure 1. Diagram depicting the screened versus non‑screened population 
and their outcomes.
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calculated. The Kaplan‑Meier survival analysis was used to 
evaluate the effect of screening on CRC incidence and mortality, 
and the cumulative incidence and cumulative mortality curves 
were determined. The Cox proportional hazards regression 
model was used to control potential confounding factors (age 
at baseline, gender, education, family history of malignant 
tumors, BMI, smoking status, alcohol intake, physical exercise, 
meat intake and aspirin use) for CRC incidence and mortality. 
SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA) was used for 
the statistical analyses. All statistical tests that were performed 
were two‑sided, and P<0.05 was considered to indicate a statis-
tically significant difference.
Results
Subjects and screening results. Fig. 1 shows a diagram depicting 
the screened vs. non‑screened population and the outcome of 
the study. For the entire 22‑year study period, there were a 
total of 5,104 eligible subjects. Of these, 3,863 participated 
in the screening for CRC (screening group) and 1,241 did not 
(non‑screening group). Over the course of the study, 231 subjects 
in the screening group and 156 in the non‑screening group 
were lost to follow‑up due to a change in residence (6.0 and 
12.6%, respectively; P=0.000). In addition, 1,588 subjects in 
the screening group and 516 in the non‑screening group had 
succumbed due to causes other than CRC (41.1 and 41.6%, 
respectively; P=0.769). Up to December, 2008, the person‑years 
of observation in the screening and non‑screening groups were 
49,566 and 15,826, respectively. The baseline characteristics 
of the subjects were not significantly different in the screening 
group compared with those in the non‑screening group (Table I).
Table II shows the results of each screening round. The posi-
tive result rates of gFOBT ranged from 4.6 to 16.2%, while FIT 
ranged from 1.1 to 2.6%. Between 1987 and 2005, 778 colonos-
copies and 33 DCBEs were performed in the screening group, 
with a total follow‑up rate of 87.0% (811/932) in patients with 
positive FIT results. A total of 36 cases of CRC occurred in the 
screening group. Among the 36 CRC cases, 25 were detected by 
the screening program, while four cases with positive FIT results 
refused to undergo follow‑up colonoscopy or DCBE, and were 
Table I. Baseline characteristics of subjects in the screening and non‑screening groups.
Characteristics Screening (n=3863) Non‑screening (n=1241) P‑value
Gender, n (%)   
  Male 2913 (75.4) 934 (75.3) 0.917
  Female   950 (24.6) 307 (24.7) 
Age (years)   
  Mean age ± SD 62.1±6.9 62.0±7.0 0.613
Education, n (%)   
  Up to high school 3549 (91.9) 1133 (91.3) 0.523
  College or higher 314 (8.1) 108 (8.7) 
Family history of malignant tumors, n (%)   
  With 118 (3.1)   31 (2.5) 0.311
  Without 3745 (96.9) 1210 (97.5) 
Body mass index   
  Mean BMI ± SD 23.1±1.6 23.2±1.6 0.736
Smoking status, n (%)   
  Never 1339 (34.7) 406 (32.7) 0.082
  Former 1120 (29.0) 401 (32.3) 
  Current 1404 (36.3) 434 (35.0) 
Alcohol intake, n (%)   
  None   747 (19.3) 244 (19.7) 0.630
  Occasional 2810 (72.7) 909 (73.2) 
  Regular 306 (7.9) 88 (7.1) 
Physical exercise, n (%)   
  <Once per week 1853 (48.0) 593 (47.8) 0.910
  ≥Once per week 2010 (52.0) 648 (52.2) 
Meat intake, n (%)   
  <3 times per week 1038 (26.9) 331 (26.7) 0.891
  ≥3 times per week 2825 (73.1) 910 (73.3) 
Aspirin, n (%)   
  No use 2957 (76.5) 958 (77.2) 0.638
  Regular use   906 (23.5) 283 (22.8) 
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later diagnosed by clinical means. Seven cases were missed due 
to a false‑negative FOBT result. The general sensitivity of this 
three‑tier FOBT was 80.6% (29/36; 95% CI, 65.3‑91.1). There 
were 153 (4.0%) subjects who were identified to have adenomas 
of ≥1 cm in size in the screening group.
Incidence and mortality rates of CRC in screening and 
non‑screening groups. During the 19‑year screening period 
(1987‑2005), 32 CRC cases occurred in the screening group 
and 20 occurred in the non‑screening group. In the last 3 years 
of follow‑up (2006‑2008), an additional four cases occurred 
in the screening group and one occurred in the non‑screening 
group (Fig. 1 and Table III). Until December 2005, the CRC 
incidence in the screening group was 0.75/1,000 person‑years, 
which was significantly lower than that of the non‑screening 
group (1.43/1,000 person‑years; P=0.027). The mortality was 
0.35/1,000 person‑years in the screening group, which was 
also significantly lower than that of the non‑screening group 
(0.93/1,000, P=0.013). The relative risks of incidence and 
mortality adjusted for the baseline characteristics of the subjects 
were 0.49 (95% CI, 0.28‑0.85) and 0.31 (95% CI, 0.14‑0.65), 
respectively (Both P<0.05; Table III). Three years subsequent 
to the termination of the screening program, the incidence and 
mortality in the screening group was significantly lower than 
that of the non‑screening group (P=0.034 and P=0.022, respec-
tively), with adjusted relative risks of 0.51 (95% CI, 0.30‑0.87) 
and 0.36 (95% CI, 0.18‑0.71), respectively (both P<0.05; 
Table III). Therefore, there was a 49% decrease in incidence and 
a 64% decrease in mortality in the screening group compared 
with the non‑screening group during the entire 22‑year study 
period. Mortality rates from all causes did not differ between 
the two groups (P=0.516 for between 1987 and 2008).
In total, the study was comprised of 4,777 subjects aged 
between 50 and 74 years, and 327 subjects aged >75 years on 
recruitment. A stratified analysis revealed that a significant 
decrease in the incidence and mortality of CRC was only 
evident in the subgroup who were aged between 50 and 
74 years (P=0.028 and P=0.024, respectively; Table IV).
Table II. Results of each annual screening round and the test performance of FOBT.
 Screened   Colonoscopy  Cancer and
 subjects gFOBT+ FIT+ or DCBE Cancer adenomas ≥1 cm
 No. of ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Year subjects n % n % n % n %a n PPVb n PPVb
1987 2246 2246 100.0 202   9.0 51 2.3 45 88.2 1 2.2 10 22.2
1988 2239 2233   99.7 175   7.8 48 2.1 39 81.3 1 2.6   8 20.5
1989 2240 2228   99.5 237 10.6 52 2.3 47 90.4 2 4.3   8 17.0
1990 2211 2205   99.7 156   7.1 47 2.1 35 74.5 0 0.0   7 20.0
1991 2184 2164   99.1 233 10.8 52 2.4 45 86.5 1 2.2 12 26.7
1992 2286 2253   98.6 254 11.3 55 2.4 49 89.1 2 4.1   8 16.3
1993 2293 2285   99.7 216   9.5 54 2.4 46 85.2 1 2.2 11 23.9
1994 2264 2251   99.4 365 16.2 58 2.6 53 91.4 2 3.8 10 18.9
1995 2308 2302   99.7 269 11.7 61 2.6 57 93.4 3 5.3 15 26.3
1996 2280 2247   98.6 271 12.1 54 2.4 51 94.4 2 3.9 11 21.6
1997 2220 2214   99.7 204   9.2 52 2.3 46 88.5 1 2.2   7 15.2
1998 2217 2201   99.3 316 14.4 50 2.3 44 88.0 1 2.3 12 27.3
1999 2255 2249   99.7 198   8.8 53 2.4 39 73.6 1 2.6   9 23.1
2000 2253 2236   99.2 215   9.6 52 2.3 50 96.2 1 2.0 14 28.0
2001 2232 2218   99.4 192   8.7 48 2.2 43 89.6 1 2.3   5 11.6
2002 2289 2273   99.3 183   8.1 45 2.0 41 91.1 1 2.4 11 26.8
2003 2457 2415   98.3 112   4.6 26 1.1 21 80.8 1 4.8   6 28.6
2004 2457 2445   99.5 227   9.3 48 2.0 36 75.0 2 5.6   6 16.7
2005 2456 2431   99.0 145   6.0 26 1.1 24 92.3 1 4.2   8 33.3
aRates were the number of colonoscopy or double‑contrast barium enema (DCBE) patients relative to the number of patients with positive fecal 
immunochemical test (FIT) results. bOnly positive tests followed by colonoscopy or DCBE were used in the computation for positive predictive 
value (PPV). gFOBT, guaiac‑based fecal occult blood test. 
Figure 2. Cumulative incidence of colorectal cancer (CRC) in the screening 
and non‑screening group by Kaplan‑Meier analysis.
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Figs. 2 and 3 show the cumulative incidence and mortality 
of CRC, as analyzed by the Kaplan‑Meier method. The differ-
ences in the cumulative incidence and mortality between the 
two groups was evident after the seventh and eighth years of 
screening, and more so thereafter.
Discussion
The current study presented a three‑tier FOBT‑based screening 
program, which has been described previously (9,10). Certain 
cross‑sectional studies for this type of combined gFOBT with 
FIT have demonstrated compatible sensitivity to gFOBT, but 
notable increased specificity (7,10). The difficulty of dietary 
Table III. Incidence and mortality rates of CRC between 1987 and 2008 (per 1000 person‑years).
 May 1987‑December 2005 May 1987‑December 2008
 --------------------------------------------------------------------------------- -----------------------------------------------------------------------------
Characteristic Screening  Non‑screening Screening  Non‑screening
Person‑years of observation 42881  13974 49566  15826
Colorectal cancer
  No. of patients 32  20 36  21
  Incidence rate 0.75  1.43 0.73  1.33
  RR (95% CI)  0.52 (0.30‑0.93)   0.55 (0.32‑0.95)
  Adjusted RR (95% CI)a  0.50 (0.29‑0.88)   0.52 (0.30‑0.89)
  Adjusted RR (95% CI)b  0.49 (0.28‑0.85)   0.51 (0.30‑0.87)
Mortality from CRC
  No. of deaths 15  13 19  14
  Mortality rate 0.35  0.93 0.38  0.88
  RR (95% CI)  0.38 (0.18‑0.81)   0.43 (0.22‑0.88)
  Adjusted RR (95% CI)a  0.31 (0.15‑0.67)   0.36 (0.18‑0.72)
  Adjusted RR (95% CI)b  0.31 (0.14‑0.65)   0.36 (0.18‑0.71)
Mortality from all causes
  No. of deaths 1225  423 1607  530
  Mortality rate 28.57  30.27 32.42  33.49
  RR (95% CI)  0.94 (0.85‑1.05)   0.97 (0.88‑1.07)
aAdjusted for age and gender. bAdjusted for age, gender, education, family history of malignant tumors, BMI, smoking status, alcohol intake, 
physical exercise, meat intake and aspirin use. CRC, colorectal cancer; RR, relative risk; CI, confidence interval.
Table IV. Incidence and mortality of CRC stratified by age (between May, 1987 and December, 2008).
 50‑74 years ≥75 years
 --------------------------------------------------------------------------- ------------------------------------------------------------------------------
 Screening Non‑screening Screening Non‑screening
No. of subjects 3614 1163 249 78
No. of CRC cases 29 (0.8%) 18 (1.5%) 7 (2.8%) 3 (3.8%)
RR (95% CI) 0.52 (0.29‑0.93)  0.71 (0.18‑2.74)
Adjusted RR (95% CI)a 0.50 (0.28‑0.90)  0.69 (0.18‑2.67)
Mortality from CRC 14 (0.4%) 11 (0.9%) 5 (2.0%) 3 (3.8%)
RR (95% CI) 0.40 (0.18‑0.89)  0.43 (0.10‑1.83)
Adjusted RR (95% CI)a 0.36 (0.16‑0.80)  0.41 (0.10‑1.74)
aAdjusted for age and gender. CRC, colorectal cancer; RR, relative risk; CI, confidence interval.
Figure 3. Cumulative mortality of colorectal cancer (CRC) in the screening 
and non‑screening groups, by Kaplan‑Meier analysis.
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restriction led to a poor specificity of guaiac‑based tests in the 
Chinese population (11). Moreover, the advantage of using a 
combined test is that it reduces the cost of the FIT assay, as 
the FIT is only developed when the gFOBT result is positive. 
The observed sensitivity for CRC detection in the present study 
was substantially greater than that identified by Allison et al (8) 
(65% for CRC) in a cross‑sectional study with a similar 
three‑tier method. This is likely to be due to the longitudinal 
nature of the present study, which meant that the cases missed in 
one screening round were identified in subsequent repeat tests.
In this 22‑year longitudinal, controlled trial involving a 
dynamic cohort, it was demonstrated that annual FOBT‑based 
screening resulted in a 49% decrease in colon cancer incidence 
and a 64% decrease in CRC‑related mortality, even 3 years after 
the termination of the screening program. The differences in 
cumulative incidence and mortality were evident between the 
two groups after only 7 to 8 years of the study, which may 
indicate that the lead time of screening is ~7‑8 years. To the 
best of our knowledge, this study is the longest follow‑up of a 
colon cancer screening trial in a developing country. The study 
included a highly stable cohort with relatively few subjects 
lost to follow‑up (<10% in the 22‑year follow‑up), but a high 
censoring rate due to mortality from other causes. The compli-
ance rate was also high (almost 100% for the first level test and 
83% for colonoscopy in patients with a positive FIT result). 
This may be ascribed partly to bringing the screening program 
to a military healthcare system.
However, the study also has several limitations. The 
population of the study consisted only of military officials 
and may not consequently be representative of the general 
Chinese population. Additionally, the study was not random-
ized; the screening group consisted of subjects who chose 
to be screened. This may have produced a selection bias, 
although the screened and non‑screened populations shared 
similar demographic features. Furthermore, there is no defi-
nite final age for the screening. Routine screening for CRC 
is recommended against in adults >75 years (12). The present 
data also revealed that the effect of screening on the incidence 
and mortality of CRC was less significant among subjects 
aged >75 years. Moreover, the sample size was relatively small 
compared with previous trials involving gFOBT. 
Taking into account the aforementioned limitations, the 
present study demonstrated that a three‑tier FOBT‑based 
annual screening, even with one fecal sample, resulted in the 
detection of >80% of CRCs. The study also revealed a marked 
decrease in CRC‑related mortality (64% after controlling 
potential confounding factors) compared with that which 
has been identified previously with gFOBT, which was in the 
range of 15 to 30% (4‑6). The present findings were similar 
to the longitudinal non‑controlled observational study in the 
Japanese population by Lee et al (13), which utilized FIT 
for screening and demonstrated a 70% decrease in mortality 
over a 13‑year study period. Moreover, there are a limited 
number of studies demonstrating an effect of FOBT on inci-
dence (14), while the present data revealed a 49% decrease 
in CRC incidence in the screening group compared with 
that in the non‑screening group. This dramatic decrease in 
the incidence and mortality of CRC may be ascribed partly 
to the higher compliance and adenoma detection rates with 
subsequent resection in the present study. In the study 4% of 
the screening subjects were identified to have adenomas of 
≥1 cm in size, while 0.8‑1.7% were identified in a previous 
study (15). However, since the present study was not random-
ized, the effect of selection bias on the differences in incidence 
and mortality observed may not be excluded, although the 
two groups (screening and non‑screening) exhibited similar 
baseline demographic characteristics. Furthermore, the 
grouping in the present study was according to the prefer-
ence of the subjects, i.e. whether to undergo CRC screening 
or not. It is supposed that individuals who refuse screening 
have higher CRC incidence and mortality rates than those 
who accept testing (16). The rates of loss to follow‑up were 
significantly higher in the non‑screening group, which may 
indicate less benefit from the military healthcare system in 
the non‑screening group compared with that in the screening 
group. All of the aforementioned factors may have contrib-
uted to the decreases in the incidence and mortality of CRC, 
along with the efficacy of the screening process.
In conclusion, when accepted, annual FOBT‑based 
screening using a three‑tier system in an average‑risk Chinese 
population aged >50 years demonstrated >80% sensitivity in 
detecting CRC. The screening significantly reduced the inci-
dence and mortality rates of CRC. These findings suggested 
that annual FOBT examination coupled with a complete colo-
noscopy follow‑up for cases with positive FOBT results is an 
effective approach for CRC control in China.
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